Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc(1) Inhibition Strategy for Malaria

Antimalarial combination therapies play a crucial role in preventing the emergence of drug-resistant Plasmodium parasites. Although artemisinin-based combination therapies (ACTs) comprise the majority of these formulations, inhibitors of the mitochondrial cytochrome bc(1) complex (cyt bc(1)) are amo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Autores principales: Stickles, Allison M., Smilkstein, Martin J., Morrisey, Joanne M., Li, Yuexin, Forquer, Isaac P., Kelly, Jane X., Pou, Sovitj, Winter, Rolf W., Nilsen, Aaron, Vaidya, Akhil B., Riscoe, Michael K.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2016
Materias:
Experimental Therapeutics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4958223/
https://ncbi.nlm.nih.gov/pubmed/27270285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00791-16
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares